Table 1 Summary of patient characteristics
n = 17 patients | |
|---|---|
Age (years) | |
Median | 28 |
Range | 18–56 |
Age classes, n (%) | |
≤ 20 years | 2 (11.8) |
21–30 years | 8 (47.1) |
31–40 years | 0 |
41–50 years | 5 (29.4) |
> 50 years | 2 (11.8) |
Gender | |
Female | 3 (17.6) |
Male | 14 (82.4) |
KPS (pre-operative), n (%) | |
90–100 | 10 (58.8) |
70–80 | 6 (35.3) |
< 70 | 0 |
No data | 1 (5.9) |
KPS (start first CT), n (%) | |
90–100 | 3 (17.6) |
70–80 | 13 (76.5) |
< 70 | 0 |
No data | 1 (5.9) |
Tumor localizationc | |
Supratentorial | 11 (64.7) |
Infratentorial | 6 (35.3) |
Extent of first resection, n (%) | |
Gross total resection | 4 (23.5) |
Subtotal resection | 5 (29.4) |
Partial resection | 5 (29.4) |
Biopsy | 2 (11.8) |
No data | 1 (5.9) |
Histology (initial) | |
Ependymoma WHO grade II | 4 (23.5) |
Anaplastic ependymoma WHO grade III | 13 (76.5) |
Histology (start first CT) | |
Ependymoma WHO grade II | 1 (5.9) |
Anaplastic ependymoma | 14 (82.4) |
Sarcoma/Gliosarcoma | 2 (11.8) |
MGMT promoter methylation status, n (%) | |
Unmethylated | 9 (52.9) |
Methylated | 3 (17.6) |
No data | 5 (29.1) |
First-line therapies beyond surgery, n (%) | |
RT alone | 9 (52.9) |
TMZ/RT → TMZ | 2 (11.8) |
No therapy | 6 (35.3) |
First salvage therapy, n (%) | |
Re-resection | |
alone | 4 (23.5) |
plus RT alone | 2 (11.8) |
plus RT plus TMZ | 2 (11.8) |
plus Bevacizumab | 1 (5.9) |
plus CTa | 2 (11.8) |
CT aloneb | 4 (23.5) |
RT alone | 1 (5.9) |
Bevacizumab alone | 1 (5.9) |
First CT, n (%) | |
TMZ | 10 (58.8) |
Procarbazine plus Lomustine plus Vincristine | 3 (17.6) |
Epirubicin plus Ifosfamide | 1 (5.9) |
Carboplatin plus Etoposide | 2 (11.8) |
Carboplatin plus Etoposide plus Vincristine | 1 (5.9) |
Number of surgical interventions | |
1 | 5 (29.4) |
2 | 3 (17.6) |
> 3 | 9 (52.9) |
Survival (from first CT) (all patients n = 17) | |
Median follow-up (months) | 39 |
Median PFS (months) (95% CI) (events) | 10 (3.4–16.6) (15) |
Median OS (months) (95% CI) (events) | 41 (31.6–50.4) (9) |
Survival (from first CT) (n = 15, patients 5 and 9 excludedd) | |
Median follow-up (months) | 39 |
Median PFS (months) (95 % CI) (events) | 6 (1.5–10.5) (14) |
Median OS (months) (95 % CI) (events) | 41 (30.0–52) (8) |